BivalirudinDirect thrombin inhibitor
Bivalirudin inhibits thrombin, a key enzyme in clot formation. Its clinical role centres on procedural anticoagulation, where preventing a dangerous clot must be balanced against causing bleeding.
What is Bivalirudin?
Bivalirudin is a synthetic peptide anticoagulant used around coronary interventions. It was developed from the idea of hirudin, a thrombin inhibitor originally identified in leeches.
How it works
It binds thrombin directly and reversibly, reducing the enzyme’s role in fibrin formation and other clotting processes.
Effects studied
Procedural clot prevention and bleeding
Clinical comparisons assess protection from clotting alongside bleeding during coronary intervention. Results depend on the heparin regimen, additional antiplatelet drugs and procedural care used as comparators. 1
Evidence: Coronary-intervention trials
What does the evidence show?
Coronary-intervention trials
How bivalirudin interrupts clotting
Bivalirudin is a synthetic peptide inspired by hirudin, the thrombin inhibitor originally identified in leeches. It binds thrombin directly and reversibly. Thrombin helps form fibrin and activate clotting processes, so inhibiting it can prevent unwanted clots during an intervention.
Why coronary procedures need protection
When a blocked coronary artery is treated with a catheter and stent, clotting risk arises alongside the injury and the procedure. Anticoagulation is part of that care. Researchers assess bivalirudin alongside the procedure and antiplatelet treatment. It is not an isolated intervention for general heart health.
What the trial comparator changes
The retained trial compares bivalirudin with a particular heparin-based strategy in coronary intervention. Bleeding differences depend partly on whether additional glycoprotein IIb/IIIa inhibitors are used and on other aspects of care. Results from one regimen should not be turned into a claim that bivalirudin is always the safest option. 1
Balancing bleeding and clotting risks
Bleeding remains the central risk, and kidney function can affect exposure. Teams also consider clotting complications around and after the procedure. This is a short-term, closely managed anticoagulant decision; it is unrelated to nutrition, exercise recovery or the broad promises sometimes attached to the word peptide.
Safety & status
Bleeding is the central risk. Kidney function affects exposure, and clotting complications around the procedure still require monitoring.
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is bivalirudin a heart-health supplement?
No. It is a procedural anticoagulant used with closely managed cardiovascular care.
Is it always safer than heparin?
No universal conclusion follows. Bleeding and clotting results depend on the comparator strategy and treatment setting. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.